Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Silence Therapeutics (NASDAQ:SLN) and raises the price target from $42 to $55.
June 28, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Silence Therapeutics and raises the price target from $42 to $55.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100